NVCR | tickerfilter.com

Fundamental analysis

44%

Profitability 25%

Dept financing 47%

Liquidity 75%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.29%

1 Month

2.75%

3 Months

-28.25%

6 Months

8.41%

1 Year

43.05%

2 Year

-72.64%

Key data

Stock price

$18.31

P/E Ratio

0.00

DAY RANGE

$17.99 - $19.02

EPS

-$0.86

52 WEEK RANGE

$12.17 - $34.13

52 WEEK CHANGE

$49.59

MARKET CAP

1.959 B

YIELD

N/A

SHARES OUTSTANDING

111.486 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-24-2025

BETA

2.22

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,133,751

AVERAGE 30 VOLUME

$888,350

Company detail

CEO: Asaf Danziger
Region: US
Website: novocure.com
Employees: 1,320
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing

NovoCure Limited engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma.

NVCR - NovoCure Ltd